Conversion of immunosuppressive monotherapy from cyclosporin A to tacrolimus reverses bone loss in rats

Calcified Tissue International

Volumn 81, Issue 2, 2007, Pages 114-123

  Spolidorio, Luís C ^a   Nassar, Patricia O ^a   Nassar, Carlos A ^a   Spolidorio, Denise M P ^a   Muscará, Marcelo N ^b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Biomarker; Cyclosporin A; Cytokine; Tacrolimus Alveolar bone loss

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CYCLOSPORIN A; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLACEBO; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ALVEOLAR BONE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE MASS; CALCIUM BLOOD LEVEL; CELL COUNT; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; RAT; TREATMENT DURATION;

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; ALVEOLAR BONE LOSS; ANIMALS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE MATRIX; CALCIUM; CELL COUNT; CELL PROLIFERATION; CYCLOSPORINE; GRAFT REJECTION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKINS; ISOENZYMES; MALE; OSTEOCLASTS; RATS; RATS, WISTAR; TACROLIMUS;

EID: 34547792433     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-007-9040-2     Document Type: Article

References (59)

1. Asberg A (2003) Interactions between cyclosporin and lipid-lowering drugs. Drugs 63:367-378
2. Segal E, Tamir A, Ish-Shalom S (2003) Compliance of osteoporotic patients with different treatment regimens. Isr Med Assoc J 5:859-862
3. Cohen A, Shane E (2003) Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int 14:617-630
4. Loertscher R, Thiel G, Harder F, Brunner FP (1983) Persistent elevation of alkaline phosphatase in cyclosporine-treated renal transplant recipients. Transplantation 36:115-116
5. Sambrook PN, Kelly PJ, Fontana D, Nguyen T, Keogh A, Macdonald P, Spratt P, Freund J, Eisman JA (1994) Mechanisms of rapid bone loss following cardiac transplantation. Osteoporos Int 4:273-276
6. Thiebaud D, Krieg MA, Gillard-Berguer D, Jacquet AF, Goy JJ, Burckhardt P (1996) Cyclosporine induces high bone turnover and may contribute to bone loss after heart transplantation. Eur J Clin Invest 26:549-555
7. Ebeling PR, Thomas DM, Erbas B, Hopper JL, Szer J, Grigg AP (1999) Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation. J Bone Miner Res 14:342-350
8. Goodman GR, Dissanayake IR, Bowman AR, Pun S, Ma Y, Jee WS, Bryer HP, Epstein S (2001) Transforming growth factor-beta administration modifies cyclosporin A-induced bone loss. Bone 28:583-588
9. Mathier MA, McNamara DM (2004) Management of the patient after heart transplant. Curr Treat Options Cardiovasc Med 6:459-469
10. Spolidorio LC, Spolidorio DMP, Nassar PO, Nassar CA, Holzhausen M, Almeida OP (2004) Influence of age on combined effects of cyclosporin and nifedipine on rat alveolar bone. J Periodontol 75:268-272
11. Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S (1988) Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 123:2571-2577
12. 3 modifies cyclosporine-induced bone loss. Calcif Tissue Int 47:152-157
13. Spolidorio LC, Marcantonio E Jr, Spolidorio DM, Nassar OP, Marcantonio RA, Rossa C Jr (2007) Alendronate therapy in cyclosporin-induced alveolar bone loss in rat. J Periodontal Res (in press)
14. Duarte PM, Nogueira Filho GR, Sallum EA, de Toledo S, Sallum AW, Nociti FH Jr (2001) The effect of an immunosuppressive therapy and its withdrawal on bone healing around titanium implants. A histometric study in rabbits. J Periodontol 72:1391-1397
15. Silva HC, Coletta RD, Jorge J, Bolzani G, de Almeida OP, Graner E (2001) The effect of cyclosporin A on the activity of matrix metalloproteinases during the healing of rat molar extraction wounds. Arch Oral Biol 46:875-879
16. Gau CH, Hsieh YD, Shen EC, Lee S, Chiang CY, Fu E (2005) Healing following tooth extraction in cyclosporine-fed rats. Int J Oral Maxillofac Surg 34:782-788
17. Marshall I (1995) Expression of interleukin-1 and interleukin-6 in bone normal and cyclosporin A treated rats. The XII International Conference on Calcium Regulating Hormones, Melbourne, Australia. Bone, vol 17, pp S12-S13
18. Lee WY, Baek KH, Rhee EJ, Tae HJ, Oh KW, Kang MI, Lee KW, Kim SW, Kim CC, Oh ES (2004) Impact of circulating bone-resorbing cytokines on the subsequent bone loss following bone marrow transplantation. Bone Marrow Transplant 34:89-94
19. Spencer CM, Goa KL, Gillis JC (1997) Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 54:925-975
20. Rinaldi M, Pellegrini C, Martinelli L, Goggi C, Gavazzi A, Campana C, Arbustini E, Grossi P, Regazzi M, Ippoliti G, Vigano M (1997) FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study. J Heart Lung Transplant 16:1001
21. Morris-Stiff G, Khan A, Quiroga I, Baboo R, Jurewicz WA (1999) Immunosuppression in renal transplantation. Meta-analysis should not have included one of the studies. BMJ 23:1136
22. Mentzer RM Jr, Jahania MS, Lasley RD (1998) Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group. Transplantation 65:109-113
23. Asante-Korang A, Boyle GJ, Webber SA, Miller SA, Fricker FJ (1996) Experience of FK506 immune suppression in pediatric heart transplantation: a study of long-term adverse effects. J Heart Lung Transplant 15:415-422
24. Swensen SJ, Morin RL, Aughenbaugh GL, Leimer DW (1995) CT reconstruction algorithm selection in the evaluation of solitary pulmonary nodules. J Comput Assist Tomogr 19:932-935
25. Cvetkovic M, Mann GN, Romero DF, Liang XG, Ma Y, Jee WS, Epstein S (1994) The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 57:1231-1237
26. Katz IA, Takizawa M, Joffe II, Stein B, Fallon MD, Epstein S (1991) Comparison of the effects of tacrolimus and cyclosporin on bone mineral metabolism in the rat. A pilot study. Transplantation 52:571-574
27. Stempfle HU, Werner C, Siebert U, Assum T, Wehr U, Rambeck WA, Meiser B, Theisen K, Gartner R (2002) The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 73:547-552
28. Inoue T, Kawamura I, Matsuo M, Aketa M, Mabuchi M, Seki J, Goto T (2000) Lesser reduction in bone mineral density by the immunosuppressant, FK506, compared with cyclosporine in rats. Transplantation 70:774-779
29. Goffin E, Devogelaer JP, Lalaoui A, Depresseux G, De Naeyer P, Squifflet JP, Pirson Y, van Ypersele de Strihou C (2002) Tacrolimus (FK506) and low-dose steroid immunosupression preserves bone mass after renal transplantation. Transpl Int 15:73-80
30. Monegal A, Navasa M, Guanabens N (2001) Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int 68:83-86
31. Scolapio JS, DeArment J, Hurley DL, Romano M, Harnois D, Weigand SD (2003) Influence of tacrolimus and short-duration prednisone on bone mineral density following liver transplantation. J Parenter Enteral Nutr 27:427-432
32. Josephson MA, Schumm LP, Chiu MY, Marshall C, Thistlethwaite JR, Sprague SM (2004) Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation 78:1233-1236
33. Guimarães MR, Nassar PO, Nassar CA, Spolidorio DMP, Rossa C Jr, Spolidorio LC (2007) protective effects of tacrolimus, a calcineurin inhibitor, in experimental periodontitis in rats. Arch Oral Biol (in press)
34. Wassef R, Cohen Z, Langer B (1985) Pharmacokinetic profiles of cyclosporine in rats. Influence of route of administration and dosage. Transplantation 40:489-493
35. Nassar CA, Spolidorio LC (2004) Effect of cyclosporin A on alveolar bone homeostasis in a rat periodontitis model. J Periodontal Res 39:143-148
36. Spolidorio LC, Holzhausen M, Spolidorio DM, Nassar CA, Nassar PO, Muscara MN (2005) Cyclosporin but not tacrolimus significantly increases salivary cytokine contents in rats. J Periodontol 76:1520-1525
37. Baldock PA, Morris HA, Need AG, Moore RJ, Durbridge TC (1998) Variation in the short-term changes in bone cell activity in three regions of the distal femur immediately following ovariectomy. J Bone Miner Res 13:1451-1457
38. Wada C, Kataoka M, Seto H, Hayashi N, Kido J, Shinohara Y, Nagata T (2006) High- turnover osteoporosis is induced by cyclosporin A in rats. J Bone Miner Metab 24:199-205
39. Ogawa K, Hori M, Tako R, Sakurada T (2005) Effects of combined elcatonin and alendronate treatment on the architecture and strength of bone in ovariectomized rats. J Bone Miner Metab 23:351-358
40. Parfitt AM (1998) Bone histomorphometry: standardization of nomenclature, symbols and units (summary of proposed system). Bone 9:67-69
41. Rodino MA, Shane E (1998) Osteoporosis after organ transplantation. Am J Med 104:459-469
42. Abdelhadi M, Ericzon BG, Hultenby K, Sjoden G, Reinholt FP, Nordenstrom J (2002) Structural skeletal impairment induced by immunosuppressive therapy in rats: cyclosporine A vs tacrolimus. Transpl Int 15:180-187
43. Kataoka M, Shimizu Y, Kunikiyo K, Asahara Y, Yamashita K, Ninomiya M, Morisaki I, Ohsaki Y, Kido JI, Nagata T (2000) Cyclosporin A decreases the degradation of type I collagen in rat gingival overgrowth. J Cell Physiol 182:351-358
44. Schlosberg M, Movsowitz C, Epstein S, Ismail F, Fallon MD, Thomas S (1989) The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology 124:2179-2184
45. Rucinski B, Liu CC, Epstein S (1994) Utilization of cyclosporine H to elucidate the possible mechanisms of cyclosporine A-induced osteopenia in the rat. Metabolism 43:1114-1118
46. Katz I, Li M, Joffe I, Stein B, Jacobs T, Liang XG, Ke HZ, Jee W, Epstein S (2000) Influence of age on cyclosporin-A induced alterations in bone mineral metabolism in the rat "in vivo." J Bone Miner Res 9:9-67
47. Rolla D, Ballanti P, Marsano L, Bianchi G, Messa P, Paoletti E, Cannella G (2006) Bone disease in long-term renal transplant recipients with severe osteopenia: a cross-sectional study. Transplantation 81:915-921
48. Ott R, Bussenius-Kammerer M, Koch CA, Yedibela S, Kissler H, Hohenberger W, Muller V (2003) Does conversion of immunosuppressive monotherapy from cyclosporine A to tacrolimus improve bone mineral density in long-term stable liver transplant recipients? Transplant Proc 35:3032-3034
49. Akahane M, Ohgushi H, Yoshikawa T, Sempuku T, Tamai S, Tabata S, Dohi Y (1999) Osteogenic phenotype expression of allogeneic rat marrow cells in porous hydroxyapatite ceramics. J Bone Miner Res 14:561-568
50. Bjoro K, Brandsaeter B, Wiencke K, Bjoro T, Godang K, Bollerslev J, Schrumpf E (2003) Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease. Scand J Gastroenterol 38:320-327
51. Schmidt CM, Orr HT (1995) HLA-G transgenic mice: a model for studying expression and function at the maternal/fetal interface. Immunol Rev 147:53-65
52. Delmas PD (1993) Biochemical markers of bone turnover. J Bone Miner Res 82:S549-S555
53. Zeni SN, Gregorio S, Gomez AC, Somoza J, Mautalen C (2002) Olpadronate prevents the bone loss induced by cyclosporine in the rat. Calcif Tissue Int 70:48-53
54. Ryffel B (1986) Cyclosporin toxicology - experimental studies. Prog Allergy 38:181-197
55. Mason J (1990) Renal side-effects of cyclosporin A. Br J Dermatol 36:71-77
56. Buchinsky FJ, Ma Y, Mann GN, Rucinski B, Bryer HP, Paynton BV, Jee WS, Hendy GN, Epstein S (1995) Bone mineral metabolism in T lymphocyte-deficient and -replete strains of rat. J Bone Miner Res 10:1556-1565
57. Yeo H, McDonald JM, Zayzafoon M (2006) NFATc1: a novel anabolic therapeutic target for osteoporosis. Ann N Y Acad Sci 1068:564-567
58. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889-901
59. Koga T, Matsui Y, Asagiri M, Kodama T, de Crombrugghe B, Nakashima K, Takayanagi H (2005) NFAT and osterix cooperatively regulate bone formation. Nat Med 11:880-885